Recombinant Human LAG3 / CD223 Protein, Fc Tag (MALS Verified), 100µg

Background
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Source
Recombinant Human LAG-3, Fc Tag (LA3-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Leu 450 (Accession # P18627-1).
Predicted N-terminus: Leu 23

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 72.8 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma"
Su, Schoenfeld, Ibrahim et al
J Immunother Cancer (2024) 12 (3)
(2) "TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells"
Cianciotti, Magnani, Ugolini et al
Front Immunol (2024) 15, 1315283
(3) "Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses"
Kelly, Landon, Zaidi et al
Nat Med (2024)
Showing 1-3 of 1592 papers.